Passive Transfer of Animal-Derived Polyclonal Hyperimmune Antibodies Provides Protection of Mice from Lethal Lassa Virus Infection.

ABSTRACT:

Background

Lassa virus (LASV) can cause severe acute systemic infection in humans. No approved antiviral drugs or vaccines are currently available. Antibody-based therapeutics are considered a promising treatment strategy in the management of LASV disease.

Methods

We used chimeric Ifnar^-/- C57BL/6 (Ifnar^{-/- Bl6}) mice, a lethal LASV mouse model, to evaluate the protective efficacy of polyclonal antibodies purified from sera of rabbits hyperimmunized with virus-like particles displaying native-like LASV glycoprotein GP spikes.

Results

Polyclonal anti-LASV GP antibodies provided 100% protection against lethal LASV infection in a pre- and post-exposure treatment setting and prevented LASV disease. Treatment also significantly lowered viremia level an

SUBMITTER: Oestereich L 

PROVIDER: S-EPMC10384048 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature